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Safety and Tolerability of NXY-059 for Acute
Intracerebral Hemorrhage
The CHANT Trial
Patrick D. Lyden, MD; Ashfaq Shuaib, MD; Kennedy R. Lees, MD; Antoni Davalos, MD;
Stephen M. Davis, MD; Hans-Christoph Diener, MD; James C. Grotta, MD;
Tim J. Ashwood, PhD; Hans-Goren Hardemark, MD; Hannah H. Svensson, MSc;
Larry Rodichok, MD; Warren W. Wasiewski, MD; Gabrielle Åhlberg, MD;
for the CHANT Trial Investigators
Background and Purpose—NXY-059 is a free radical–trapping neuroprotectant developed for use in acute ischemic
stroke. To facilitate prompt administration of treatment, potentially before neuroimaging, we investigated the safety of
NXY-059 in patients with intracerebral hemorrhage (ICH).
Methods—We randomized 607 patients within 6 hours of acute ICH to receive 2270 mg intravenous NXY-059 over 1 hour
and then up to 960 mg/h over 71 hours, or matching placebo, in addition to standard care. The primary outcome was
safety: the mortality and the frequency of adverse events, and the change from baseline for a variety of serum, imaging,
and electrophysiological measurements. We also studied the overall distribution of disability scores on the modified
Rankin Scale (mRS) and the Barthel index.
Results—We treated 300 patients with NXY-059 and 303 with placebo. Treatment groups were well matched for
prognostic variables including Glasgow Coma Scale, risk factors, and age. The mean National Institute of Health Stroke
Scale score on admission was 14 in both groups. The baseline hemorrhage volume was 22.420.1 mL in the NXY-059
group and 23.322.8 mL in the placebo group (meanSD). Most hemorrhages were related to hypertension or
anticoagulant use. Mortality was similar in both groups: 20.3% for NXY-059 and 19.8% for placebo-treated patients.
The proportion of patients who experienced an adverse event was the same for both groups, whereas for serious adverse
events the proportion was slightly higher in the NXY-059 group. However, no pattern emerged to indicate a safety
concern. Serum potassium fell transiently in both groups, lower in the NXY-059 group. There were no differences in
3-month function, disability, or neurological deficit scores. The odds ratio for an improved outcome in 3-month mRS
scores in the NXY-059 group was 1.01 (95% CI 0.75, 1.35).
Conclusions—NXY-059 given within 6 hours of acute ICH has a good safety and tolerability profile, with no adverse
effect on important clinical outcomes. (Stroke. 2007;38:2262-2269.)
Key Words: acute care  clinical trials  free radical scavengers  neuroprotectants  neuroprotection
 neuroprotective agents  stroke management
Intracerebral hemorrhage (ICH) accounts for 15% of allstrokes globally, and is associated with substantially
greater mortality and worse functional outcomes than ische-
mic stroke.1,2 Although ICH confers higher mortality and
morbidity than acute ischemic stroke, the 2 types of strokes
present similarly; thrombolytic treatment for ischemic stroke
must therefore be delayed for cerebral imaging to exclude
ICH.3 Such delays in diagnosis and specialized care are
associated with worse outcome.4–7 Treatment delay could be
avoided if a therapy were safe enough in all stroke patients,
ischemic or hemorrhagic, to be used before baseline brain
imaging.8 To use an agent without first imaging the brain
would require a demonstration of safety and tolerability in
ICH patients. Ideally, such a drug would have efficacy not
only in ischemic stroke but also in ICH. However, it remains
unclear whether efficacy in both clinical entities would be
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possible because some cell injury mechanisms may differ
between the 2 forms of stroke.9
Tissue oxidation via free radical–initiated processes medi-
ates ischemia-related damage in the brain.10–12 NXY-059
(disufenton sodium) is a novel free radical–trapping agent
which reduces infarct size and preserves brain function in
animal models of acute ischemic and hemorrhagic stroke.13–16
Neuroprotection was shown in rat models of transient and
permanent focal ischemia using measures of lesion volume
when the drug was given as late as 5 hours after ischemia.13,17
Improvements in functional outcomes, including motor defi-
cits, spatial neglect, as well as reduction in infarction volume
were demonstrated in primates after permanent ischemia.18 A
protective effect after 10 weeks was noted when therapy was
delayed as late as 4 hours after ischemia.19
SAINT-I (Stroke-Acute Ischemic NXY Treatment) estab-
lished the efficacy of NXY-059 in patients with acute
ischemic stroke.20 NXY-059 significantly reduced disability
assessed on the mRS at 90 days compared with placebo and
was generally well tolerated with no significant safety con-
cerns. In patients treated with recombinant tissue plasmino-
gen activator (rt-PA) and NXY-059, the incidence of symp-
tomatic ICH was only 2.5% compared with 6.4% in the
rt-PA–treated patients receiving placebo in place of the
NXY-059.21 None of these beneficial effects could be repli-
cated in a second trial, SAINT 2, however (Shuaib A, et al,
unpublished data, 2007).
During the SAINT 2 study, we sought to explore the safety
and potential for efficacy of NXY-059 treatment in a large
number of patients with ICH in the Cerebral Hematoma And
NXY Treatment trial (CHANT). We studied safety by mea-
suring mortality and the frequency of serious adverse events
and adverse events; we collected functional outcome data to
assure the drug did not negatively impact long-term neuro-
logical recovery after hemorrhage and to explore a potential
neuroprotective effect. We tested for potential efficacy by
measuring hematoma growth during the infusion period,
because hematoma growth was recently shown to signifi-
cantly influence outcome.22
Methods
Study Design
CHANT was a randomized, double-blind, placebo-controlled trial
conducted at 131 SAINT 2 study sites in 20 countries (please see
appendix for a list of study sites). The trial was approved by local
and national institutional review boards. Informed consent was
obtained from the patient or legally acceptable surrogate. The
steering committee assisted in developing the trial protocol, ap-
proved the statistical plan, had full access to the data, wrote the
manuscript, and was responsible for decisions regarding publication.
The principal investigator assumes full responsibility for the integ-
rity and interpretation of the data. The sponsor, AstraZeneca, was
responsible for operational aspects of the trial including collecting
and storing the data and performing analysis according to the
approved plan. An independent data safety monitoring board for-
mally conducted a safety review after 200 patients were enrolled.
Patients
Patients 18 years of age or older with a clinical diagnosis of acute
ICH confirmed by brain imaging were included. The protocol
allowed enrollment if there were small amounts of hemorrhage
outside the parenchyma associated with large primary ICH, but not
if the hemorrhage was deemed to arise primarily from a location
outside the brain. Patients were to manifest limb weakness as part of
the presenting deficit, and onset of symptoms within the previous 6
hours was required. If the onset time was unknown, the last time the
patient was known to be well was assumed to be the onset time.
Other key selection criteria are summarized in Table 1.
Study Intervention
Patients were randomly assigned to receive an intravenous infusion
of placebo (normal saline) or NXY-059 as a loading infusion over 1
hour, which was followed by a maintenance infusion over 71 hours.
TABLE 1. Selection Criteria Used in CHANT
Inclusion Exclusion
1. Written informed consent from the
patient or legally acceptable
representative.
1. Acute ischemic stroke, an epidural, subdural or subarachnoid hemorrhage, a tumor (including those
associated with a hemorrhage), encephalitis, or any diagnosis other than acute ICH. Note: Small areas of
epidural, subdural, or subarachnoid hemorrhage associated with large primary ICH were allowed.
2. Males and females 18 years old. 2. ICH attributable to trauma. Patients who suffered minimal head trauma following the onset of a primary
ICH were allowed.
3. Clinical diagnosis of acute stroke with
limb weakness and a neuroimaging scan
(CT or MRI) showing an ICH.
3. Unconsciousness (i.e., score of 3 on item 1a. of the NIHSS).
4. Severe concurrent illness with life expectancy less than 6 months.
5. Planned surgical removal of the ICH. Minor surgical procedures such as ventriculostomy or intracranial
pressure (ICP) monitor placement were allowed.
6. Patients unlikely to complete the 72-hour infusion of investigational product because of a severe clinical
condition at baseline.
7. Known severe renal disorder from the patient’s history. Patients with a known calculated creatinine
clearance of 30 mL/min using the Jaffe method or 35 mL/min using the modified Jaffe or enzymatic
method to determine SCreatinine were excluded.
8. Current known alcohol or illicit drug abuse or dependence.
9. Pregnancy or breast-feeding. Women of childbearing potential were excluded unless a negative test for
pregnancy has been obtained before randomization.
10. Treatment since onset of stroke symptoms with experimental (ie, drugs in clinical studies) or empirical
treatments for stroke with the exception of mannitol, glycerol, and steroids for the treatment of ICP.
11. Treatment with acetazolamide and methotrexate during the 72-hour infusion.
12. Previous inclusion in CHANT or concurrent inclusion in another clinical study with an investigational drug
or device, or participation in any previous clinical study within 30 days of admission assessment and start
of NXY-059.
4. The sum of scores on items 5 and 6 on
the NIHSS were 2 at baseline and the
total score (items 1–11) was 6.
5. Onset of symptoms within 6 hours of the
planned start of investigational product
infusion. Onset time for patients who
awoke with symptoms was the last time
the patient was awake without symptoms
of stroke.
6. Premorbid mRS score of 0 or 1.
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Treatment could commence up to 6 hours after stroke onset, but each
site was urged to begin treatment as early as possible. Randomization
was performed by a central interactive voice response system
accessed by telephone. We stratified randomization for country and
total ICH score (0, 1, 2, 3)23 at admission, which is based on
location and size of the hematoma, involvement of ventricles, age,
and the Glasgow Coma Scale.24 The Glasgow Coma Scale is not
validated for use specifically in stroke patients, but indicates the
level of consciousness in brain injured patients.
The study drug was prepared for infusion to a final concentration
of 15 mg/mL in 0.9% saline, with NXY-059 and placebo (0.9%
saline) in vials of identical appearance. No laboratory or adverse
events were known to identify active drug from placebo. The loading
rate was 151 mL/h for all patients (2270 mg/h). After 1 hour the
infusion rate was reduced to 64 mL/h. Estimated creatinine clearance
(ClCr) based on a serum creatinine measurement, age, sex, and
weight25 was used to determine the need for further rate adjustment
within the first 4 hours (to 44 mL/h for ClCr 51 to 80 mL/min and
32 mL/h for ClCr of 30 to 50 mL/min), to achieve and maintain a
target mean unbound steady state concentration of 260 mol/L.
Patients with estimated ClCr below 30 mL/min were to be withdrawn
from treatment. Patients otherwise received standard of care for
acute ICH.
Clinical Assessments
To assure no adverse impact on patient safety attributable to
NXY-059, patients were assessed at enrolment, 24 and 72 hours, and
7 and 90 days after the start of infusion, using the National Institutes
of Health Stroke Scale (NIHSS).26,27 Follow-up assessments after 7,
30, and 90 days included functional measures: the modified Rankin
Scale (mRS),28 the Barthel Index (BI),29 and the patient rated Stroke
Impact Scale (90 days only).30a To improve the application of the
disability and neurological scales, investigators were trained, tested,
and certified in use of mRS, using a DVD-based method developed
for the SAINT trials30b and the NIHSS using methods developed and
validated by the National Institutes of Health.27
Imaging
Patients underwent a second neuroimaging scan at end of infusion
(72 hours for those who completed the infusion). Additional scans
were performed on patients that showed deterioration in their
neurological status—worsening of 4 or more points on the NIHSS—
any time from the start of investigational product infusion through 21
days. The qualifying and all follow-up scans were read centrally,
blinded to treatment allocation. Hematoma volumes were estimated
locally and centrally using the ellipsoid approximation.31 The anal-
ysis of change in volume from baseline to 72 hours was adjusted for
baseline volume. In addition, the central reader computed volumes
using semiautomated planimetry and reconstruction. The presence of
intraventricular hemorrhage was scored locally and centrally, as was
the presence or absence of blood in the subarachnoid, subdural, or
epidural spaces. The central reader used a detailed mapping grid to
score the locations involved with hematoma to semiquantitatively
describe lesion locations. Magnetic resonance images (MRI) were
allowed in place of qualifying or follow-up CT scans if the MRI
scanning protocol were approved in advance as sufficient to detect
hemorrhage reliably.
Safety Assessments
During infusions, vital signs and adverse events were recorded.
Routine laboratory tests were undertaken for central analysis at
enrolment, and after 24 hours, 72 hours, and 7 days. Patients were
contacted by telephone 30 days after the start of infusion to ascertain
their status, query for any serious adverse events, and to obtain a
rating on the modified Rankin Scale32 and estimated Barthel index.33
Follow-up ratings were obtained in person 72 days and 9010
days after the start of infusion. Serious adverse events were collected
from the signing of consent through study completion 90 days later.
Statistical Analysis
The sample size was determined based on projected recruitment rates
at SAINT 2 study sites during the time planned for the study, rather
than a power analysis based on a hypothesized event rate. With 600
patients assumed recruited, the study would have 80% power to
detect a 5% absolute increase in adverse event reports, assuming a
2% rate in the placebo group. There was 90% power to detect a 6%
increase. All patients in whom study infusion began were analyzed
for safety, according to treatment received. If patients dropped out of
the study because of death, the maximum score was assigned for
their last rating on appropriate efficacy variables. For patients
dropping out of the study before Day 90, for reasons other than
death, the last available observation was used as last rating.
The primary analysis of all-cause mortality rate was performed
with a logistic regression model adjusting for total ICH score and
total NIHSS score at baseline. The difference between treatment
groups was assessed with log-rank test. Cox proportional odds
regression was used to assess the possible influence of prognostic
factors. The treatment by exploratory factor interaction was investi-
gated by use of logistic regression.
Adverse events and observed laboratory values were summarized
and shift tables were generated to detect any clinically significant
laboratory abnormalities in change of values from baseline to end of
TABLE 2. Baseline Characteristics and Timing of Treatment in CHANT
Field Total NXY PLAC
No. randomized 607 305 302
No. treated 603 300 303
Females/Males 214/389 111/189 103/200
Average time to onset of infusion
Hours:minSD
4:201:04 4:191:04 4:211:04
Infratentorial origin N (%) 14 (2.3) 5 (1.7) 9 (3)
Average age, years (range) 66.1 (29–93) 66.6 (40–93) 65.7 (29–92)
NIHSS, mean (range) median 14 (6–33) 14 14 (6–33) 13 14 (6–28) 13
GCS, average (range) median 13.8 (7–15) 15 13.7 (7–15) 15 13.9 (7–15) 15
IVH, n 168 83 85
ICH volume (ML), meanSD (range) 22.821.5 (0.5–144) 22.420.1 (1–123) 23.322.8 (0.5–144)
ICH score, mean (range median) 0.9 (0–4) 1 0.9 (0–4) 1 0.9 (0–4) 1
Glucose on admission, mmol/l 7.73.0 7.82.7
Selected baseline characteristics of the treatment groups are listed. Abbreviations as defined in the text. The groups are well
balanced with respect to important characteristics that might influence safety or response to therapy.
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infusion. Change from baseline in cerebral imaging (CT or MRI) was
summarized and described at the end of infusion/72 hours. Also,
changes from baseline to the time of any new stroke within 21 days
were summarized.
The full categorized modified Rankin Scale scores were compared
between treatment groups using the Cochran-Mantel-Haenszel
(CMH) test with modified ridits. Logistic regression was applied to
the modified Rankin Score data at last rating to assess for explana-
tory variables. Total NIHSS score and change from baseline in total
NIHSS score were compared between treatment groups using a
CMH test with modified ridit score.
Results
Recruitment into CHANT was completed in September 2005,
with 603 patients treated (607 randomized; Table 2 and Figure
1). The number of patients randomized was 305 into NXY-059
treatment and 302 into placebo. One patient in each group was
lost to follow-up. The central readings generally confirmed the
investigator’s readings, however in 1 NXY-059 and 3 placebo
treated patients, the central read did not confirm the presence of
primary ICH. Because of these exclusions or misrandomiza-
tions, the number of patients who received treatment was 300
NXY-059 and 303 placebo (Figure 1).
The 2 groups were generally well matched with respect to
important baseline characteristics that influence outcome
after ICH (Table 2) and with respect to medical history (Table
3). Atrial fibrillation was slightly more common in the
NXY-059 group; diabetes and prior use of antithrombotics
was slightly more common in the placebo group.
The overall unbound plasma concentration of NXY-059 at
66 to 72 hours was 295.8109.9 mol/L (meanSD, n203).
Mortality within 3 months of ICH was 61 (20.3%) for
NXY-059–treated and 60 (19.8%) for placebo-treated pa-
tients; life table analysis showed no difference between the
groups at any time after treatment (Figure 2). Time to death
was not significantly different (P0.86, log-rank test).
Investigators reported adverse events in 265 (88.3%)
NXY-059–treated patients and in 266 (87.8%) placebo-
treated patients, or 1094 events in the NXY-059 group
compared with 1121 events in the placebo group. The pattern
of adverse events was similar in the 2 groups. Serious adverse
events were reported by investigators in 138 (46.0%) NXY-
Figure 1. Trial profile and disposition of
enrolled patients. FADS indicates full
analysis data set. Other abbreviations as
in the text.
TABLE 3. Medical History
Medical History
NXY-059,
n300 n (%)
Placebo,
n303 n (%)
Hypertension 240 (80) 252 (83.2)
Previous ischemic stroke 34 (11.3) 33 (10.9)
Myocardial ischemia 18 (6.0) 27 (8.9)
Atrial fibrillation, past or current 35 (11.7) 25 (8.3)
Diabetes mellitus 49 (16.3) 63 (20.8)
Prior use of antiplatelets 65 (21.7) 77 (25.4)
Prior use of anticoagulants 22 (7.3%) 21 (6.9%)
Selected items from the medical histories are summarized for each
treatment group. There are no differences between the study groups.
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059 –treated patients (202 events) compared with 121
(39.9%) placebo–treated patients (173 events). There was no
consistent pattern to this difference and it was to a larger
extent because of serious adverse events occurring beyond 1
week after end of study drug infusion. The incidence of the
most common serious adverse events during the study is
shown in Table 4. The most frequent event was stroke in
evolution, and its incidence was similar in the 2 treatment
groups (NXY-059 21.7% versus placebo 22.4%). Treatment
was discontinued because of an adverse event in 18 (6.0%)
NXY-059–treated and 20 (6.6%) placebo-treated patients;
there were no differences in the incidence and type of serious
adverse events leading to death (data not shown). There was
no relationship between adverse events, serious adverse
events, or mortality and creatinine clearance or steady-state
plasma NXY-059 concentration (data not shown).
The mean serum potassium fell transiently in both treat-
ment groups, with a nadir occurring by 72 hours after infusion
began and recovering to baseline levels by 1 week (Figure 3).
The decrease was greater in the NXY-059–treated patients.
Hypokalemia was reported as an adverse event more fre-
quently in patients receiving NXY-059 compared with pla-
cebo (17.7% versus 13.2% during the study, 13.7% versus
10.6% during infusion). There was no difference in other
routine laboratory values and no difference in incidence of
abnormalities and change from baseline in ECG parameters
and vital signs.
There was no difference between the treatment groups for
functional or neurological outcome. The distribution of the
modified Rankin scores was similar in both groups at all time
points (Figure 4). Similarly, there were no differences be-
tween the groups in the NIHSS, Barthel Index, and Stroke
Impact Scale (data not shown).
Average hematoma volumes in the groups were similar at
baseline: 22.420.1 mL (range 0.9 to 123.1 mL) in the
NXY-059 group and 23.322.8 mL (0.5 to 144.4 mL) in the
placebo group (meanSD). Hematoma growth was slightly
less in the NXY-059 group versus placebo, comparing
baseline to 72 hours after treatment onset (Table 5), but not
significantly different. Similarly, edema growth was compa-
rable in both groups at baseline and after 72 hours of drug
infusion (Table 5). There were no differences in volumes or
hematoma growth noted when comparing patients presenting
within 3 hours from onset to those presenting later. From the
semi-quantitative brain maps, new brain areas were scored on
the 72-hour scans (indicating hemorrhage extension) in 75
(26.0%) of NXY-059–treated patients, compared with 71
(24.5%) of placebo-treated patients. Considering only the
patients with a serious adverse event report consistent with
neurological deterioration or hemorrhage expansion, new
brain regions were scored on the follow-up scans in 21/70
NXY-059 patients compared with 25/63 placebo-treated pa-
tients (not significant, chi-square). A ventricular drain was
inserted in 20 NXY-059 and 11 placebo treated patients.
Surgical evacuation of the ICH was performed in 4 NXY-059
and 5 placebo patients.
Figure 2. Life table analysis of mortality in the CHANT trial.
TABLE 4. No. (%) of Patients With Adverse Events During the
Overall Study Period
Serious Adverse Event
NXY-059
(n300)
Placebo
(n303)
Stroke in evolution 65 (21.7%) 68 (22.4%)
Pneumonia 17 (5.7%) 17 (5.6%)
Pulmonary embolism 7 (2.3%) 4 (1.3%)
Hemorrhagic stroke 6 (2.0%) 4 (1.3%)
Respiratory failure 6 (2.0%) 4 (1.3%)
Pneumonia aspiration 6 (2.0%) 8 (2.6%)
Arteriovenous malformation 5 (1.7%) 3 (1.0%)
Sepsis 4 (1.3%) 5 (1.7%)
Depressed level of consciousness 3 (1.0%) 0 (0.0%)
Ischemic stroke 3 (1.0%) 3 (1.0%)
Respiratory distress 3 (1.0%) 2 (0.7%)
Urinary tract infection 3 (1.0%) 0 (0.0%)
Neurological symptom 2 (0.7%) 3 (1.0%)
Respiratory tract infection 2 (0.7%) 3 (1.0%)
Adverse events were collected from investigator reports. This table lists the
most common reported events, in order of frequency, from the overall study
period (90 days). There are no significant differences. Similar tables covering
just the study drug infusion period, or just the first week after enrollment,
similarly showed no differences.
Figure 3. Serum potassium after enrollment into CHANT. At
baseline and then after enrolment at 24 hours, 72 hours, or the
end of the study drug infusion (EOI), or at 7 days, the mean
(95% CI) serum potassium was calculated for each group.
Although the differences are statistically significant after 24 and
72 hours, there were no adverse events or other clinical mani-
festations associated with this finding.
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Discussion
This trial of NXY-059 treatment for acute ICH achieved the
prespecified primary end point of safety: we detected no
important differences between the groups with respect to
adverse events, serious adverse events, or mortality (Table 4).
CHANT was planned to run in SAINT 2 study sites, and the
sample size was based on recruitment projections in those
sites, not on a hypothesized event rate. With the numbers of
patients recruited, the study had, for example, 80% power to
detect a 5% absolute increase in adverse event reports,
assuming a 2% rate in the placebo group. There was 90%
power to detect a 6% increase. Small increases in adverse
event frequency would require far greater numbers for detec-
tion. The groups were well balanced with respect to all
important variables that might influence safety, and hence the
data suggest NXY-059 appears to have a good safety profile
in ICH patients. Although CHANT is the largest study
completed to date of an investigational agent in ICH patients,
the number of studied patients is small in relation to the
potential clinical use of the drug.
In the CHANT trial, NXY-059 was associated with statis-
tically significantly increased rates of hypokalemia, although
the absolute reduction in serum potassium was small relative
to placebo. An analogous finding was observed in the SAINT
1 trial of NXY-059 for ischemic stroke.20 No data are
available to suggest a mechanism for this effect. There was no
associated adverse event or serious adverse event that oc-
curred with the observed reduction in serum potassium, so the
effect lacks any clinical significance in these study popula-
tions. Nonetheless, surveillance of serum potassium and other
electrolytes are recommended as part of standard acute stroke
management, with or without NXY-059 treatment.
NXY-059 had no effect on functional outcome, as mea-
sured by several accepted and valid rating scales (Figure 4).
These data suggest that even if some subtle increase in the
frequency of adverse events was overlooked in this trial, no
adverse impact on functional outcome could be detected.
Further, NXY-059 therapy did not exacerbate the natural
enlargement of ICH over 72 hours after treatment; hemor-
rhage enlargement is an independent prognostic determinant
of mortality and functional outcome.22 If anything, the data
are more consistent with attenuation of hemorrhage growth.
CHANT is the largest clinical trial to test the safety or
efficacy of a neuroprotectant in patients with ICH. Three
other trials of drugs with mechanisms very different from
NXY-059—GAIN, CLASS-H, and IMAGES—used similar
methods, and also found no effect, beneficial or harmful.34–36
GAIN included 571 patients with presenting characteristics
similar to CHANT; the agent studied, gavestinel
(GV150526), blocks the glycine site of the n-methyl-D-
aspartate receptor. In GAIN-ICH, mortality was 20% overall
and similar in the 2 groups. The relatively smaller CLASS-H
trial tested the safety of a GABA agonist, clomethiazole, in
96 ICH patients, compared with placebo in 102 ICH patients.
In CLASS-H, the groups were imbalanced with respect to
important variables that influence outcome, and the mortality
was nominally higher in the clomethiazole group, compared
with placebo, although multivariable logistic regression sug-
gested the difference was attributable to the baseline imbal-
ances, not the drug. In the IMAGES trial, magnesium was
administered to 125 ICH patients and placebo to 122 ICH
patients. The odds ratio for unfavorable outcome was 0.82
(95% CI 0.44 to 1.53). Taking CHANT, IMAGES, GAIN,
and CLASS-H together, however, despite the fact that NXY-
059 has a very different mechanism of action, suggests that
putative neuroprotectants—at least for the classes of agents
studied—to date appear to exhibit a good safety profile in
ICH patients. No efficacy signal is apparent in the accumu-
lated experience with neuroprotection to date.
We studied the safety of NXY-059 in an ICH population
with similar severity of symptoms to that accumulated in the
ischemia trials, SAINT-I and SAINT-2. Overall, these results
suggest that NXY-059 is well tolerated with no safety
concerns observed in ICH patients studied to date. No
differences in the frequency of adverse events, serious ad-
verse events, or mortality emerged from the study data. We
found no treatment effect on functional outcome, either
positive or negative, as measured by valid stroke rating
scales. Hematoma volumes were similar in the 2 groups at
Figure 4. Functional outcome: modified Rankin Scale at 90 days. There was no difference in the distribution of modified Rankin
Scale scores between the 2 treatment groups. Numbers within the panels are percentages, rounded to nearest decimal.
TABLE 5. Hematoma and Edema Volume Change From
Baseline at 72 Hours
Variable
NXY-059
(n287)
Placebo
(n288)
P
Value
Hematoma Volume change, mL 4.5 (1.5)* 6.7 (1.5) 0.188
Edema Volume change, mL 16.7 (1.4) 17.8 (1.4) 0.442
Total, mL 20.6 (2.6) 23.7 (2.6) 0.260
Baseline and 72 hours scans were compared for evidence of hemorrhage
and edema. The difference between 72 hours and baseline volume was
calculated for each patient, and the group means calculated after correcting for
baseline volume. The resulting mean growth in lesion volume was compared
between the 2 groups; there were no statistically significant differences.
*Least Squares Mean (SE).
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baseline and 72 hours after treatment. There is no suggestion
that NXY-059 benefits ICH patients.
Appendix
The following participated in the CHANT study. Steering Commit-
tee: K.R. Lees, Glasgow, United Kingdom (chair); P. Lyden, San
Diego, United States (Principal Investigator, CHANT); T.J. Ash-
wood, So¨derta¨lje, Sweden (sponsor representative); A. Davalos,
Barcelona, Spain; S. Davis, Melbourne, Australia; H.-C. Diener,
Essen, Germany; J. Grotta, Houston, United States; A. Shuaib,
Edmonton, Canada; W.W. Wasiewski, Wilmington, United States
(sponsor representative). Data and Safety Monitoring Board: S.
Pocock, London, United Kingdom (chair); H. Adams, Iowa, United
States; P. Bath, Nottingham, United Kingdom; D. Oakes, Rochester,
United States; N.-G. Wahlgren, Stockholm, Sweden. Study Team
Leader: K. Svensson, So¨derta¨lje, Sweden. Study Team Physicians:
H.-G. Hårdemark, G. Åhlberg, So¨derta¨lje, Sweden; L. Rodichok,
Wilmington, United States. Study Team Statisticians: H.H. Svens-
son, So¨derta¨lje, Sweden; V. Alderfer, U. Emeribe Wilmington,
United States. Clinical Coordinating Center: UCSD Clinical Trials
Coordinating Center, P. Lyden, Coordinating Investigator, K. Rapp,
Project Manager. Contract Research Organizations: Perceptives
Informatics (IVRS system and neuroimaging); Diagnostic Tech-
nology and Services Research Technology Limited (Central ECG
reader); Covance Central Laboratory Services SA (Central Laboratory).
Clinical Centers
CHANT Study Investigators (Enrollment)
Australia: S. Davis, Melbourne (4); C. Staples, Brisbane (1); C. Levi,
New Castle (1); C. Bladin, Melbourne (8); G. Donnan, Melbourne
(2); D. Crimmins, Gosford (4); R. Gerraty, Melbourne (3). Belgium:
G. Vanhooren, Brugge (2); P. De Deyn, Antwerpen (6); V. Thijs,
Leuven (5); C. Willems, Hasselt (2); E. Urbain, Montignies-sur-
Sambre (2). Brazil: A. Massaro, Sao Paulo (1); M.A. Friedrich, Porto
Alegre (2). Bulgaria: P. Stamenova, Sofia (4); D. Minchev, Varna
(2); V. Platikanov, Pleven (7); T. Notcheva, Russe (9). Canada: A.
Shuaib, Edmonton (10); D. Selchen, Mississauga (10); P. Teal,
Vancouver (3); S. Phillips, Halifax (2); C. Voll, Saskatoon (4); D.
Howse, Thunder Bay (2); L. Berger, Greenfield Park (3);
D. Gladstone, Toronto (4). Czech Republic: J. Bauer, Prague (4); M.
Bar, Ostrava-Poruba (9); D. Vaclavik, Ostrava-Vitkovice (10); H.
Lachmann, Prague (9); O. Skoda, Pelhrimov (5). France: C. Lucas,
Lille (3); P. Amarenco, Paris (16); P. Labauge, Nimes (1); F. Ziegler,
Belfort (1); T. Moulin, Besancon (3); J. Bouillat, Bourg En Bresse
(4); A. Bonafe, Montpellier (2); D. Sablot, Perpignan (3); B. Guillon,
Saint Herblain (4). Germany: H.C. Diener, Essen (2); J. Glahn,
Minden (4); D. Schneider, Leipzig (11); C. Weiller, J. Liepert,
Hamburg (4); A. Hetzel, T. Els, Freiburg (8); P. Vogel, Hamburg (5).
Hong Kong: L. Wong, Hong Kong (5); P.W. Ng, Hong Kong
(1). Hungary: N. Szegedi, Budapest (20); L. Csiba, Debrecen (4); S.
Horva´th, Kistarcsa (5); A. Csa´nyi, Gyo¨r (8); J. Nikl, Zalaegerszeg
(1); B. Clemens, Debrecen (17). Italy: G. Micieli, Pavia (5); G.
Agnelli, Perugia (1). New Zealand: A. Barber, Auckland (4).
Portugal: L. Cunha, Coimbra (7); M. Correia, Porto (3); V. Salgado,
Amadora (10); G. Gonc¸alves, Coimbra (3). Singapore: I. Ng,
Singapore (15); N. Chou, Singapore (5); J. Thomas, Singapore (3).
Slovak Republic: M. Brozman, Nitra (8); M. Nye´ky, Roznava (2); J.
Vyletelka, Zilina (6); M Dvora´k, Levoca (11); E. Kurca, Martin (4);
J. Here´nyiova´, Lucenec (1). South Africa: J. Gardiner, Cape Town
(1); J. Thorne, George (1); J. Roos, Somerset West (5); M. Isaacs,
Morningside (1). South Korea: J.-S. Kim, Seoul (6); B.-C. Lee,
Anyang-Si (5). Spain: J. Serena Leal, Gerona (18); J Roquer,
Barcelona (6); E. Dı´ez Tejedor, Madrid (2); J. Matias Guiu, J.M.
Molto Jorda, Alicante (5); A. Chamorro, Barcelona (14); F. Nom-
bella, Madrid (3); J. Castillo, Santiago (5); J.R. Gonza´lez Marcos,
Sevilla (8); A. Da´valos, Badalona (17); J. Alvarez Sabin, Barcelona
(16); F. Rubio, Barcelona (2). United Kingdom: K. Lees, Glasgow
(3); G. Ford, Newcastle-on-Tyne (1). United States: M. Nash,
Decatur, Ga (13); N. Iannuzzi III, Winston-Salem, NC (9); J. Grotta,
Houston, Tex (7); B. Cucchiara, Philadelphia, Pa (6); J. Harris, Ft.
Lauderdale, Fla (6); T. Hemmen/P. Lyden, San Diego, Calif (6);
W. Holt, Port Charlotte, Fla (6); M. Tremwell, Ft. Smith, Ariz (6);
C. Chang, Honolulu, Hawaii (5); D. Chiu, Houston, Tex (5); H.
Sachdev, San Jose, Calif (4); L. Wechsler, Pittsburgh, Pa (4); E.
Wilson, Bristol, Tenn (4); B. Demaerschalk, Phoenix, Ariz (3); J.
Kooiker/J. McDowell, Olympia, Wash (3); K. Levin, Ridgewood, NJ
(3); J. Sander, Toledo, Ohio (3); R. Silbergleit, Ann Arbor, Mich (3);
R. Stephens, Concord, Calif (3); R. Brooks, Schenectady, NY (2); N.
Culligan, Danbury, Conn (2); B. Dandapani, Melbourne, Fla (2); J.
Gebel, Louisville, Ky (2); C. Graffagnino, Durham, NC (2); J.
Hanna, Cleveland, Ohio (2); D. Heiselman, Akron, Ohio (2); K. Ng,
Ocala, Fla (2); W. Truax, Marrero, La (2); P. Akins, Sacramento,
Calif (1); S. Arkin, Kansas City, Mo (1); F. Chang, Ft. Wayne, Ind
(1); C. Gomez, Birmingham, Ala (1); M. Jacoby, Des Moines, Iowa
(1); L. Larsen, Holmdel, NJ (1); A. Majid, East Lansing, Mich (1);
S. Mallenbaum, Virginia Beach, Va (1); G. Newman, Madison, Wis
(1); N. Papamitsakis, Edison, NJ (1); A. Turel Jr, Danville, Pa (1).
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